Glenmede Trust’s PROVECTUS BIOPHARMACEUTICALS, INC. (DE) PVCT Stock Holding History

Glenmede Trust’s Portfolio PVCT Stock Details PVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-5,000	Closed	–	–	2972
2017 Q2	$0	Hold	5,000	–	–	﹤0.01%	2735
2017 Q1	$0	Hold	5,000	–	–	﹤0.01%	2840
2016 Q4	$0	Hold	5,000	–	–	﹤0.01%	2745
2016 Q3	$0	Hold	5,000	–	–	﹤0.01%	2760
2016 Q2	$1K	Hold	5,000	–	–	﹤0.01%	2516
2016 Q1	$1K	Hold	5,000	–	–	﹤0.01%	2573
2015 Q4	$1K	Hold	5,000	–	–	﹤0.01%	2610
2015 Q3	$2K	Hold	5,000	–	–	﹤0.01%	2550
2015 Q2	$2K	Hold	5,000	–	–	﹤0.01%	2494
2015 Q1	$4K	Hold	5,000	–	–	﹤0.01%	2304
2014 Q4	$4K	Hold	5,000	–	–	﹤0.01%	2352
2014 Q3	$5K	Hold	5,000	–	–	﹤0.01%	2254
2014 Q2	$4K	Buy	+5,000	New	+$5.99K	﹤0.01%	2198

Other funds holding PVCT

HFBOT

Home Federal Bank of Tennessee Knoxville, Tennessee $463M AUM 24.62% 1-Year Est. Return

Glenmede Trust's PVCT Position: Q3 2017 in Review

Glenmede Trust sold out of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) in Q3 2017, closing a stake of 5,000 shares.

Glenmede Trust first reported a position in PVCT in Q2 2014 and held it in 13 quarters. The position peaked at $5K in Q3 2014. 2 funds tracked by Wall St. Rank hold PVCT as of Q3 2017.

Glenmede Trust reported no remaining PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position as of Q3 2017 after selling out during the quarter.
Glenmede Trust sold 5,000 PROVECTUS BIOPHARMACEUTICALS, INC. (DE) shares in Q3 2017.
Glenmede Trust first reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in Q2 2014 and held it in 13 quarters.
Glenmede Trust's PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position peaked at $5K in Q3 2014.
2 funds tracked by Wall St. Rank held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) as of Q3 2017.

Based on Glenmede Trust's 13F filing for Q3 2017, filed 14 Nov 2017.